Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

Videos

Syed A. Hussain, MD, on Neoadjuvant Treatment With Nintedanib for Locally Advanced Disease

News

Neoadjuvant Ipilimumab Plus Nivolumab Under Study in Urothelial Carcinoma

Medical Literature

Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma

Medical Literature

Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update

Medical Literature

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

News

ASTRO 2020: Predicting Survival Outcomes in Bladder Cancer Using Urinary Tumor DNA

News

ASTRO 2020: Bladder-Sparing Radiochemotherapy Regimens Under Study

Thomas Flaig, MD, on Advances in Bladder Cancer Treatment: Expert Perspective

Aristotelis Bamias, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv [Coming Soon]

View More

More

News

ASTRO 2020: Bladder-Sparing Radiochemotherapy Regimens Under Study

Whole-Genome Sequencing Via Urine: Novel Modality for Detecting Urothelial Carcinoma

Novel Urine DNA Methylation Assay Under Study in Bladder Cancer

ESMO 2020: Link Between TMB and Pembrolizumab Response in Urothelial Cancer?

FDA in Brief: Draft Guidance for Uniform Approach to Clinical Trials in Bladder Cancer

ASTRO 2020: Combination Radiotherapy and Durvalumab in Localized Bladder Cancer

Effect of Proton Pump Inhibitors on Response to Atezolizumab in Urothelial Cancer

Neoadjuvant Dual Checkpoint Blockade for High-Risk Urothelial Carcinoma

View More

Advertisement

Published

Medical Literature

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

View More

Ongoing

CE Activities

Current Topics In Management Of Non-Muscle Invasive Bladder Cancer

A Multidisciplinary Approach To Individualized Patient Care - Bladder Cancer

New Therapeutic Developments In Urothelial Cancer: Clinical Trial Evidence And Expert Guidance

New Thinking, New Strategies in Advanced Urothelial Carcinoma

View More

Available

Clinical Trials

Biomarker Identification for Bladder Cancer Patients

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.